Anaptysbio Stock Investor Sentiment
| ANAB Stock | USD 24.96 0.16 0.64% |
About 76 percent of AnaptysBio's investors are selling. The analysis of the overall investor sentiment regarding AnaptysBio suggests that quite a large number of traders are terrified. The current market sentiment, together with AnaptysBio's historical and current headlines, can help investors time the market. In addition, many technical investors use AnaptysBio stock news signals to limit their universe of possible portfolio assets.
AnaptysBio |
AnaptysBio Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards AnaptysBio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about AnaptysBio that are available to investors today. That information is available publicly through AnaptysBio media outlets and privately through word of mouth or via AnaptysBio internal channels. However, regardless of the origin, that massive amount of AnaptysBio data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of AnaptysBio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of AnaptysBio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to AnaptysBio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive AnaptysBio alpha.
AnaptysBio Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 1300 shares by Orwin John A of AnaptysBio subject to Rule 16b-3 | 09/13/2024 |
2 | Disposition of 10000 shares by Dennis Mulroy of AnaptysBio at 40.13 subject to Rule 16b-3 | 09/16/2024 |
3 | Disposition of 3780 shares by Eric Loumeau of AnaptysBio at 38.4103 subject to Rule 16b-3 | 09/17/2024 |
4 | Disposition of 1500 shares by Lizzul Paul F. of AnaptysBio at 38.67 subject to Rule 16b-3 | 09/23/2024 |
5 | Disposition of 5000 shares by Eric Loumeau of AnaptysBio at 14.02 subject to Rule 16b-3 | 10/14/2024 |
6 | AnaptysBio Shares Plunge as Eli Lilly Ends Arthritis Drug Research | 10/30/2024 |
7 | Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update | 11/05/2024 |
8 | AnaptysBio Inc Q3 2024 Earnings Revenue Soars to 30M, EPS Beats Estimates at -1.14 | 11/06/2024 |
9 | AnaptysBio Third Quarter 2024 Earnings Beats Expectations | 11/07/2024 |
10 | Down -32.84 percent in 4 Weeks, Heres Why You Should You Buy the Dip in AnaptysBio | 11/08/2024 |
11 | AnaptysBio Price Target Lowered to 66.00 at JPMorgan Chase Co. | 11/13/2024 |
12 | Truist maintains hold on AnaptysBio with 30 target | 11/19/2024 |
13 | Disposition of 2000 shares by Lizzul Paul F. of AnaptysBio at 40.0 subject to Rule 16b-3 | 11/22/2024 |
14 | Are Medical Stocks Lagging AnaptysBio This Year | 11/25/2024 |
Complementary Tools for AnaptysBio Stock analysis
When running AnaptysBio's price analysis, check to measure AnaptysBio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AnaptysBio is operating at the current time. Most of AnaptysBio's value examination focuses on studying past and present price action to predict the probability of AnaptysBio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AnaptysBio's price. Additionally, you may evaluate how the addition of AnaptysBio to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |